Blocking p38 signalling inhibits chondrogenesis in vitro but not ankylosis in a model of ankylosing spondylitis in vivo

Annals of the Rheumatic Diseases

Volumn 71, Issue 5, 2012, Pages 722-728

  Braem, Kirsten ^a   Luyten, Frank P ^a   Lories, Rik J U ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BONE MORPHOGENETIC PROTEIN; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROINFLAMMATORY CYTOKINE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG RESPONSE; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TOE JOINT;

ANIMALS; ANKYLOSIS; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CHONDROCYTES; CHONDROGENESIS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION; IMIDAZOLES; MALE; MICE; MICE, INBRED DBA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERIOSTEUM; PYRIDINES; SIGNAL TRANSDUCTION; SMAD PROTEINS; SPONDYLITIS, ANKYLOSING; TRANSFORMING GROWTH FACTOR BETA;

EID: 84859508989     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200377     Document Type: Article

References (32)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90. (Pubitemid 46590387)
2. Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465-70.
3. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127
4. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
5. van der Heijde D, Landewé R, Baraliakos X, et al.; Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
6. Lories RJ, Derese I, de Bari C, et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
7. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. (Pubitemid 40814665)
8. Nohe A, Hassel S, Ehrlich M, et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002;277:5330-8. (Pubitemid 34968578)
9. Gallea S, Lallemand F, Atfi A, et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001;28:491-8. (Pubitemid 32410000)
10. Guicheux J, Lemonnier J, Ghayor C, et al. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003;18:2060-8. (Pubitemid 37377457)
11. Ehrlich M, Horbelt D, Marom B, et al. Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell Signal 2011;23:1424-32.
12. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2. (Pubitemid 35425238)
13. Coulthard LR, White DE, Jones DL, et al. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009;15:369-79.
14. Greenblatt MB, Shim JH, Zou W, et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010;120:2457-73.
15. Studer RK, Bergman R, Stubbs T, et al. Chondrocyte response to growth factors is modulated by p38 mitogen-activated protein kinase inhibition. Arthritis Res Ther 2004;6:R56-64.
16. Bobick BE, Kulyk WM. Regulation of cartilage formation and maturation by mitogen-activated protein kinase signaling. Birth Defects Res C Embryo Today 2008;84:131-54. (Pubitemid 351957224)
17. De Bari C, Dell'Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 2001;44:85-95. (Pubitemid 32113122)
18. Chen P, Vukicevic S, Sampath TK, et al. Osteogenic protein-1 promotes growth and maturation of chick sternal chondrocytes in serum-free cultures. J Cell Sci 1995;108(Pt 1):105-14.
19. Lories RJ, Daans M, Derese I, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006;54:1736-46. (Pubitemid 43877923)
20. Badger AM, Griswold DE, Kapadia R, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000;43:175-83. (Pubitemid 30368227)
21. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996;279:1453-61. (Pubitemid 27166795)
22. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81. (Pubitemid 37129445)
23. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41.
24. Kumar S, Jiang MS, Adams JL, et al. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 1999;263:825-31. (Pubitemid 29490712)
25. Görtz B, Hayer S, Tuerck B, et al. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005;7:R1140-7.
26. Lories RJ, Derese I, Luyten FP, et al. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008;26:96-102. (Pubitemid 351385261)
27. Godl K, Wissing J, Kurtenbach A, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 2003;100:15434-9. (Pubitemid 38021007)
28. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
29. Zwerina J, Hayer S, Redlich K, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72. (Pubitemid 43228620)
30. Lories RJ, Matthys P, de Vlam K, et al. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis 2004;63:595-8. (Pubitemid 38530208)
31. Brown MA. Non-major-histocompatibility-complex genetics of ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20:611-21. (Pubitemid 43843067)
32. Zinovieva E, Bourgain C, Kadi A, et al. Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet 2009;5:e1000528.